Potential of an anti-bevacizumab idiotype scFv DNA-based immunization to elicit VEGF-binding antibody response

Abstract

Anti-idiotype antibodies have been considered for vaccination approaches against different diseases, including cancers. Based on that, we previously described an anti-bevacizumab idiotype monoclonal antibody, 10.D7, that revealed detectable antitumor effects on a vascular endothelial growth factor (VEGF)-dependent tumor model. Herein, we evaluated the possible applicability of a single-chain variable fragment (scFv) for the 10.D7 antibody in a gene immunization strategy. After checking that mammalian cells transfected to express the 10.D7 scFv are recognized by bevacizumab, it was explored the ability of our scFv construction, in a gene-based scheme, to elicit an immune response containing VEGF-binding antibodies. The results provide evidence that the designed 10.D7 scFv construct maintains the anti-bevacizumab idiotype features and has potential to activate an immune response recognizing VEGF.

Evaluating combined bevacizumab and XELOX in advanced colorectal cancer: Serum markers carcinoembryonic antigen, carbohydrate antigen 125, carbohydrate antigen 199 analysis

“…Related studies have shown that adjuvant therapy with targeted drugs can improve efficacy by effectively reducing the damage of chemotherapy to normal cells in the body[ 13 - 15 ]. Bevacizumab (BEV), a monoclonal antibody with targeted effects, can inhibit tumor growth and metastasis by inhibiting the formation of tumor neovascularization caused by the binding of vascular endothelial growth factor (VEGF) to its receptor[ 16 , 17 ]. Research has provided evidence that the utilization of BEV in conjunction with adjuvant chemotherapy can significantly enhance long-term efficacy[ 18 , 19 ].…”

Consequences of Immunoglobulin Domain-Containing Protein Retro-Proteins

“…ScFv contains the complete antigen-binding domain of an intact antibody. ScFv fragments have found great medical applications [12]. Several approaches have been employed to increase the affinity, avidity and structural stability related to these antibody fragments [12,13].…”

“…ScFv fragments have found great medical applications [12]. Several approaches have been employed to increase the affinity, avidity and structural stability related to these antibody fragments [12,13]. Among all strategies to engineer ScFv antibodies there is no attempt to use the retro-protein approach.…”